< Back to latest news & events

Event

Seminar: Strategies and updates on patenting inventions relating to personalised medicine in Europe and the US – Basel

October 2019

Event date: 17th October 2019

HGF is hosting a seminar in Der Teufelhof Basel on Thursday 17th October at 6pm. Partner Dr Leena Contarino and Patent Director Dr Laurence Gainey will consider strategies for patenting inventions in Europe and the US.

Targeted intervention (also known as personalised medicine or precision medicine) is a rapidly evolving field of medicine in which treatments are selected based on the detection of disease markers in individual patients. This enables doctors to prescribe treatment regimens that are tailored to individual patients’ medical needs.

Targeted intervention is already well established modern oncology where new drugs are now often approved together with companion diagnostics used to identify particular markers or genetic mutations in a patient. It is likely that targeted intervention will also become a feature in other therapy areas as the technology evolves. Patenting and enforcing patents covering personalised medicine inventions can be challenging, most notably in the USA.

This seminar will consider strategies for patenting these inventions in Europe and the US, including an update on the evolving situation in the US such as: legislative efforts, USPTO updated guidance and recent court cases such as Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC (Fed. Cir. July 3, 2019).

To register please email ldavies@hgf.com.

Latest updates

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article

Agritech Thymes: Unlocking the Soil Microbiome: Driving Agritech Innovation in the UK

The UK offers an ideal platform for harnessing the untapped potential of soil and plant microorganisms. Although much of my professional experience has focused on the human microbiome, I have …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting of …

Read article
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article